AI for early-phase clinical trials: from hype to proof of concept
Growing experience suggests that artificial intelligence could potentially transform how cancer research is designed and conducted
Is artificial intelligence a reliable partner for multidisciplinary tumour boards?
Real-world findings show moderate-to-high concordance between AI-generated and human experts decisions
New treatment modalities in gastrointestinal malignancies: broadening the therapeutic horizon
Rapid advances in molecular targeting, immunotherapy optimisation and novel drug classes are reshaping gastrointestinal oncology
From bottleneck to breakthrough: rethinking clinical data collection in the age of AI
Every day, clinicians generate thousands of reports containing critical data that will never be analysed. Not because it lacks value — but because extracting it remains a bottleneck.
ctDNA is unlocking new clinical opportunities for liquid biopsy
Testing standardisation and optimal integration for routine clinical use remain challenging
Early-phase studies point to efficacy of a nectin-4-targeting antibody-drug conjugate in cervical cancer
In advanced or metastatic disease, bulumtatug fuvedotin shows promising efficacy and manageable safety
The antibody–drug conjugate era in gynaecological cancers
Recent approvals are driving a shift toward biomarker-informed treatment strategies, rational combinations and personalised sequencing
Targeting the CD47-SIRPα axis continues to show promise in solid tumours
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
First-line dual targeting combination shows encouraging, durable responses in triple-negative breast cancer
A manageable safety profile was also reported for pumitamig plus the antibody-drug conjugate DB-1305/BNT325 in an early-phase study
Multimodal AI biomarkers: from biology to patient stratification
Artificial intelligence is enabling a new class of biomarkers by integrating histology, molecular data, imaging, and clinical records to generate scalable, biologically grounded insights for precision oncology.